Geode Capital Management, LLC Cara Therapeutics, Inc. Transaction History

Geode Capital Management, LLC

  • $1.21 Trillion
  • Q3 2024

A detailed history of Geode Capital Management, LLC transactions in Cara Therapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 452,249 shares of CARA stock, worth $117,584. This represents 0.0% of its overall portfolio holdings.

Number of Shares
452,249
Previous 472,686 4.32%
Holding current value
$117,584
Previous $122,000 14.75%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$0.26 - $0.38 $5,313 - $7,766
-20,437 Reduced 4.32%
452,249 $140,000
Q2 2024

Aug 09, 2024
SELL
$0.24 - $0.92 $131,739 - $504,999
-548,913 Reduced 53.73%
472,686 $122,000
Q1 2024

May 13, 2024
BUY
$0.52 - $1.05 $6,572 - $13,272
12,640 Added 1.25%
1,021,599 $929,000
Q4 2023

Feb 13, 2024
BUY
$0.6 - $1.65 $21,658 - $59,561
36,098 Added 3.71%
1,008,959 $746,000
Q3 2023

Nov 13, 2023
BUY
$1.67 - $3.33 $64,393 - $128,401
38,559 Added 4.13%
972,861 $1.63 Million
Q2 2023

Aug 11, 2023
BUY
$2.83 - $4.94 $118,811 - $207,396
41,983 Added 4.7%
934,302 $2.64 Million
Q1 2023

May 15, 2023
BUY
$4.89 - $12.27 $171,071 - $429,253
34,984 Added 4.08%
892,319 $4.38 Million
Q4 2022

Feb 13, 2023
BUY
$8.88 - $12.77 $329,989 - $474,545
37,161 Added 4.53%
857,335 $9.21 Million
Q3 2022

Nov 14, 2022
BUY
$8.24 - $12.56 $16,026 - $24,429
1,945 Added 0.24%
820,174 $7.68 Million
Q2 2022

Aug 12, 2022
BUY
$7.45 - $13.84 $101,349 - $188,279
13,604 Added 1.69%
818,229 $7.47 Million
Q1 2022

May 13, 2022
SELL
$9.94 - $12.65 $361,845 - $460,497
-36,403 Reduced 4.33%
804,625 $9.78 Million
Q4 2021

Feb 11, 2022
BUY
$11.99 - $18.14 $46,425 - $70,238
3,872 Added 0.46%
841,028 $10.2 Million
Q3 2021

Nov 12, 2021
BUY
$11.55 - $16.06 $516,435 - $718,090
44,713 Added 5.64%
837,156 $12.9 Million
Q2 2021

Aug 13, 2021
BUY
$12.38 - $29.19 $872,851 - $2.06 Million
70,505 Added 9.77%
792,443 $11.3 Million
Q1 2021

May 12, 2021
BUY
$15.07 - $21.71 $693,928 - $999,680
46,047 Added 6.81%
721,938 $15.7 Million
Q4 2020

Feb 12, 2021
BUY
$12.72 - $16.16 $393,912 - $500,442
30,968 Added 4.8%
675,891 $10.2 Million
Q3 2020

Nov 13, 2020
BUY
$12.34 - $17.92 $162,382 - $235,809
13,159 Added 2.08%
644,923 $8.21 Million
Q2 2020

Aug 13, 2020
BUY
$12.39 - $17.33 $289,306 - $404,655
23,350 Added 3.84%
631,764 $10.8 Million
Q1 2020

May 14, 2020
BUY
$9.12 - $17.78 $619,740 - $1.21 Million
67,954 Added 12.57%
608,414 $8.04 Million
Q4 2019

Feb 13, 2020
BUY
$16.11 - $25.98 $244,630 - $394,506
15,185 Added 2.89%
540,460 $8.71 Million
Q3 2019

Nov 12, 2019
BUY
$18.28 - $26.91 $1.44 Million - $2.12 Million
78,922 Added 17.68%
525,275 $9.6 Million
Q2 2019

Aug 14, 2019
BUY
$17.68 - $21.57 $855,765 - $1.04 Million
48,403 Added 12.16%
446,353 $9.6 Million
Q1 2019

May 14, 2019
BUY
$14.41 - $19.64 $427,170 - $582,208
29,644 Added 8.05%
397,950 $7.81 Million
Q4 2018

Feb 13, 2019
BUY
$12.45 - $23.47 $257,055 - $484,585
20,647 Added 5.94%
368,306 $4.79 Million
Q3 2018

Nov 13, 2018
BUY
$17.57 - $23.95 $1.72 Million - $2.34 Million
97,706 Added 39.09%
347,659 $8.33 Million
Q2 2018

Aug 14, 2018
BUY
$11.6 - $19.27 $242,416 - $402,704
20,898 Added 9.12%
249,953 $4.79 Million
Q1 2018

May 15, 2018
BUY
$11.77 - $16.08 $38,617 - $52,758
3,281 Added 1.45%
229,055 $2.84 Million
Q4 2017

Feb 13, 2018
BUY
$11.86 - $14.08 $39,541 - $46,942
3,334 Added 1.5%
225,774 $2.76 Million
Q3 2017

Nov 14, 2017
BUY
$12.6 - $16.34 $46,103 - $59,788
3,659 Added 1.67%
222,440 $3.05 Million
Q2 2017

Aug 14, 2017
BUY
N/A
218,781
218,781 $3.37 Million

Others Institutions Holding CARA

# of Institutions
74
Shares Held
12.8M
Call Options Held
0
Put Options Held
0
View Full List

About Cara Therapeutics, Inc.

CARA Quotes by TradingView
  • Ticker CARA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,725,900
  • Market Cap $14M
  • Description
  • Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...
More about CARA
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email